Sarcoidosis following alemtuzumab treatment for multiple sclerosis
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Despite proven efficacy of alemtuzumab in multiple sclerosis (MS), approximately 50% of individuals will develop a new autoimmune disease following treatment. To date these have largely been antibody mediated and organ specific (primarily affecting the thyroid gland). In a retrospective case series of 187 patients from two UK specialist centres (Cardiff and Cambridge) followed up for a median of 10 years, we report 3 (1.6%) cases of sarcoidosis following alemtuzumab treatment of MS. This report increases the spectrum of auto-inflammatory disease following alemtuzumab and should be considered by clinicians when using this therapeutic agent for MS.
Description
Keywords
Multiple sclerosis, alemtuzumab, Adult, Alemtuzumab, Antibodies, Monoclonal, Humanized, Autoimmune Diseases, Female, Humans, Male, Multiple Sclerosis, Retrospective Studies, Sarcoidosis, Treatment Outcome, Young Adult
Journal Title
Multiple Sclerosis
Conference Name
Journal ISSN
1477-0970
1477-0970
1477-0970
Volume Title
Publisher
SAGE Publications
Publisher DOI
Sponsorship
Medical Research Council (G1100114)
Wellcome Trust (105924/Z/14/Z)
Wellcome Trust (105924/Z/14/Z)